PRPH

Across TCGA pan-cancer cohorts, PRPH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPH data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRPH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRPH expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where PRPH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.849	0.654	.001	56	view →
GBM	OS	Tertile	All	0.248	0.650	<.001	28	view →
LUAD	DFS	Quartile	All	0.709	0.349	.008	11	view →
LSCC	OS	Tertile	II,III,IV	0.861	1.000	.037	3	view →
CCRCC	DFS	Quartile	All	0.874	1.000	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPH–PDAC (DFS)

Open the PDAC breakdown →